A fading sense of smell is one of the earliest and most common warning signs of Parkinson’s disease, often appearing years before the tremors and stiffness that lead to a diagnosis. Researchers have found that the loss can precede the disease’s movement symptoms by up to a decade, making it a potentially valuable early clue. The symptom is not proof of Parkinson’s on its own, but its strong association with the disease has made smell a focus of research into detecting the condition sooner.
Why smell fades before movement problems appear
Parkinson’s disease is best known for its motor symptoms, including tremor, rigidity, and slowed movement, which arise as the brain loses cells that produce dopamine. But the disease process appears to begin elsewhere in the nervous system before it reaches the regions that control movement. The olfactory system, which handles the sense of smell, is among the first areas affected. Diminished smell, known clinically as hyposmia, is present in an estimated 90 percent of people with Parkinson’s, making it one of the most reliable non-motor features of the disease. Overviews of the disease and its early signs are published by the National Institute of Neurological Disorders and Stroke.
The timing is what makes the symptom significant. Smell loss can emerge five to 10 years or more before the motor symptoms that typically prompt a diagnosis. That long lead time offers a window, at least in theory, during which the disease is underway but not yet obvious.
The biology behind the early signal
The link between smell and Parkinson’s is grounded in how the disease spreads through the brain. Parkinson’s is associated with the buildup of a protein called alpha-synuclein, which forms clumps that damage nerve cells. Autopsy studies have found this pathology in the olfactory tract and related structures early in the disease course, even before it becomes widespread. One influential hypothesis holds that the disease process may begin in the nose or the gut and travel along neural pathways into the brain, which would help explain why smell is affected so early. Research on smell loss as a marker of the disease is indexed in the biomedical literature maintained by the National Library of Medicine.
Because the olfactory system sits at this early crossroads of the disease, damage there produces a measurable deficit long before the dopamine-producing regions deteriorate enough to disrupt movement. That sequence is what gives smell testing its potential as an early indicator.
How smell loss is measured
Clinicians assess the sense of smell with standardized tests rather than relying on a patient’s own impression, which can be unreliable. One widely used tool is a scratch-and-sniff questionnaire that asks a person to identify a series of common odors, such as banana, licorice, or cinnamon, from multiple-choice options. A consistently low score can flag hyposmia. Such tests are inexpensive and non-invasive, which is part of their appeal for research into early detection. Patient-focused guidance on smell loss and Parkinson’s is provided by the Parkinson’s Foundation.
The catch is specificity. A reduced sense of smell is common in the general population and has many causes, so a single low score does not point to Parkinson’s on its own.
Why smell loss is a clue, not a diagnosis
Smell can decline for many reasons that have nothing to do with Parkinson’s. Aging itself dulls the sense, and viral infections, chronic sinus disease, head injury, smoking, and other neurological conditions such as Alzheimer’s disease can all impair it. That overlap means hyposmia is a sensitive but nonspecific marker: most people with Parkinson’s have it, but most people with smell loss do not have Parkinson’s. For that reason, clinicians treat diminished smell as one piece of a larger picture rather than a stand-alone test. It carries the most weight when it appears alongside other early features, such as certain sleep disorders, constipation, or subtle changes in movement.
The push toward earlier detection
The practical interest in smell loss stems from a broader goal: finding Parkinson’s before it causes disability. There is currently no cure, and treatments manage symptoms rather than halting the underlying damage. But researchers hope that identifying people in the earliest, prodromal phase could one day allow interventions that slow or prevent progression, if such therapies are developed. Smell testing, combined with other markers and emerging biological tests, is part of that effort to build a reliable early-warning profile. For now, the message from the research is measured: a persistent, unexplained decline in the sense of smell is worth mentioning to a physician, not as cause for alarm, but as one signal among several that may merit attention.
The interest in smell also reflects a wider shift in how neurologists think about Parkinson’s, viewing it not as a disease that begins when tremors appear but as a process that unfolds silently for years beforehand. That reframing has spurred efforts to assemble panels of early markers, combining smell testing with sleep behavior, subtle motor changes, and emerging laboratory tests that look for the misfolded proteins associated with the disease. No single one of these is decisive, but together they may eventually allow doctors to identify the disease in its earliest stages with far greater confidence than a smell test alone can provide.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
